Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers

Metabolism: Clinical and Experimental

Volumn 58, Issue 7, 2009, Pages 1002-1007

  Karakas, Sidika E ^a,b   Almario, Rogelio U ^a   Kim, Kyoungmi ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID; FATTY ACID BINDING PROTEIN 4; GLUCOSE; INSULIN; LIPID;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SAMPLE;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; FATTY ACID-BINDING PROTEINS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-1BETA; INTERLEUKIN-6; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 66349128493     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.02.024     Document Type: Article

References (30)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
3. Makowski L., and Hotamisligil G.S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 16 (2005) 543-548
4. Roden M. Blocking fatty acids' mystery tour: a therapy for metabolic syndrome?. Cell Metab 6 (2007) 89-91
5. Stejskal D., and Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?. Eur J Clin Invest 36 (2006) 621-625
6. Xu A., Wang Y., Xu J.Y., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 52 (2006) 405-413
7. Tuncman G., Erbay E., Hom X., et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 103 (2006) 6970-6975
8. Furuhashi M., Fucho R., Gorgun C.Z., Tuncman G., Cao H., and Hotamisligil G.S. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 118 (2008) 2640-2650
9. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., and Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274 (1996) 1377-1379
10. Furuhashi M., Tuncman G., Gorgun C.Z., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447 (2007) 959-965
11. Makowski L., Boord J.B., Maeda K., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7 (2001) 699-705
12. Pirro M., Mauriege P., Tchernof A., et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis 160 (2002) 377-384
13. Shankar S.S., and Steinberg H.O. FFAs: do they play a role in vascular disease in the insulin resistance syndrome?. Curr Diab Rep 5 (2005) 30-35
14. Bergman R.N., Kim S.P., Hsu I.R., et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 120 (2007) S3-S8 [discussion S29-32]
15. Ohmura E., Hosaka D., Yazawa M., et al. Association of free fatty acids (FFA) and tumor necrosis factor-alpha (TNF-alpha) and insulin-resistant metabolic disorder. Horm Metab Res 39 (2007) 212-217
16. Boston R.C., and Moate P.J. A novel minimal model to describe NEFA kinetics following an intravenous glucose challenge. Am J Physiol Regul Integr Comp Physiol (2008)
17. Ferrannini E., Camastra S., Coppack S.W., Fliser D., Golay A., and Mitrakou A. Insulin action and non-esterified fatty acids. The European Group for the Study of Insulin Resistance (EGIR). Proc Nutr Soc 56 (1997) 753-761
18. Shen W.J., Liang Y., Hong R., et al. Characterization of the functional interaction of adipocyte lipid-binding protein with hormone-sensitive lipase. J Biol Chem 276 (2001) 49443-49448
19. Shen W.J., Sridhar K., Bernlohr D.A., and Kraemer F.B. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci USA 96 (1999) 5528-5532
20. Pierson Jr. R.N., Wang J., and Thornton J.C. Measurement of body composition: applications in hormone research. Horm Res 48 Suppl 1 (1997) 56-62
21. Bergman R.N., Zaccaro D.J., Watanabe R.M., et al. Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes 52 (2003) 2168-2174
22. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
23. Kasim-Karakas S.E., Almario R.U., Gregory L., Wong R., Todd H., and Lasley B.L. Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 615-620
24. Cabre A., Lazaro I., Girona J., et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 195 (2007) e150-e158
25. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
26. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin endocrinol Metab 86 (2001) 1930-1935
27. Hotta K., Funahashi T., Bodkin N.L., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50 (2001) 1126-1133
28. Coll B., Cabre A., Alonso-Villaverde C., et al. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis (2007)
29. Hu W.H., Qiao J., Li R., and Wang L.N. Relations of serum adipocyte fatty acid binding protein to sex hormone and lipoproteins in patients with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi 86 (2006) 3186-3189
30. Karpisek M., Stejskal D., Kotolova H., et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest 37 (2007) 637-642